Results 51 to 60 of about 598,741 (306)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. [PDF]

open access: yes, 2019
PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA ...
Fanta, Paul T   +13 more
core   +1 more source

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. [PDF]

open access: yes, 2007
Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy.
Bose, Ron   +5 more
core   +1 more source

The newfound relationship between extrachromosomal DNAs and excised signal circles

open access: yesFEBS Letters, EarlyView.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom

open access: yesPulmonary Therapy
Introduction The use of oral anticancer medications has become more prevalent in cancer therapy. This is particularly the case in the management of advanced non-small cell lung cancer (NSCLC).
Joshua R. Coulter   +8 more
doaj   +1 more source

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

open access: yesМедицинский совет, 2019
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily.
K. K. Laktionov   +7 more
doaj   +1 more source

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. [PDF]

open access: yes, 2009
To address the biological heterogeneity of lung cancer, we studied 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression with full annotation for major known somatic mutations in this cancer.
Brennan, C   +18 more
core   +2 more sources

PICALM::MLLT10 translocated leukemia

open access: yesFEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen   +7 more
wiley   +1 more source

pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance

open access: yesActa Biochimica et Biophysica Sinica
EGFR protein trafficking is critical for regulating multiple biological processes, including cell growth and survival. However, how EGFR protein homeostasis is maintained remains unclear. In this study, we show that a reduction in plasma membrane-associated EGFR triggers EGFR transcription by promoting pSTAT3 nuclear localization.
Ao Juan   +10 more
openaire   +4 more sources

Transient changes in serum renalase concentration during long-distance running: The case of an amateur runner under continuous training

open access: yesJournal of Physical Fitness and Sports Medicine, 2017
Renalase is a recently discovered flavin adenine dinucleotide (FAD)-dependent soluble monoamine oxidase. It is expressed principally in the kidney, but its expression in the heart, brain, and skeletal muscle has also been confirmed.
Yasuko Yoshida   +6 more
doaj   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy